Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.84 |
| ▸ | TUBB | P07437 | 4/20 | 0.84 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.84 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.84 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.84 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.84 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.84 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.84 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.84 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.84 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.84 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.84 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.84 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.84 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
| ▸ | P4HB | P07237 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371283 | 1.00 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18389685 | 1.00 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26212394 | 1.00 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14669823 | 1.00 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19601281 | 1.00 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17213337 | 0.96 | TUBB4A (0.86) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23193005 | 0.96 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL835527 | 0.96 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12371281 | 0.96 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL835433 | 0.96 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037411-B2 | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037411-B2 | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220049001-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11142578-B2 | Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100215669-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7662936-B2 | detect, screen, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates, antibodies, and fragments and metabolites thereof, by affinity separation, chromatography, and mass spectrometry; monomethyl auristatin drug and a thio-ether linkage | GENENTECH, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100003766-A1 | screening cysteine engineered antibodies for thiol reactivity; using antibodies or antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor or cancer cells | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090286258-A1 | ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY | GENENTECH, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7521541-B2 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENETECH INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | GENENTECH, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142578-B2 | Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof | MET, HGF, HGFAC | TUBB4A 1078/4885TUBB 831/4885TUBA3C 1138/4885 |
| US-20220049001-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | TUBB4A 1078/4885TUBB 831/4885TUBA3C 1138/4885 |
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | CTH, LNPEP, CARS1 | TUBB4A 843/4885TUBB 781/4885TUBA3C 393/4885 |
| US-20090202536-A1 | ANTIBODY-DRUG CONJUGATES AND METHODS | ERBB2, EGFR, ERBB4 | TUBB4A 1049/4885TUBB 1421/4885TUBA3C 1997/4885 |
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | TUBB4A 323/4885TUBB 358/4885TUBA3C 793/4885 |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | CCR7, BCL6, CXCR3 | TUBB4A 746/4885TUBB 607/4885TUBA3C 472/4885 |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | CTH, LNPEP, CARS1 | TUBB4A 843/4885TUBB 781/4885TUBA3C 393/4885 |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | TUBB4A 2535/4885TUBB 2712/4885TUBA3C 1054/4885 |
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | FGFR2, FGFR3, FGFR1 | TUBB4A 708/4885TUBB 518/4885TUBA3C 722/4885 |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | TUBB4A 661/4885TUBB 610/4885TUBA3C 976/4885 |
| US-20100215669-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | TUBB4A 231/4885TUBB 122/4885TUBA3C 345/4885 |
| US-12037411-B2 | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof | AGBL2, ERBB2, CD22 | TUBB4A 901/4885TUBB 681/4885TUBA3C 1690/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | TUBB4A 231/4885TUBB 122/4885TUBA3C 345/4885 |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | ALB, LNPEP, CSTB | TUBB4A 104/4885TUBB 35/4885TUBA3C 537/4885 |
| US-20080171040-A1 | Maytansinoids linked to antibody which binds to ErbB receptor, or which binds tumor-associated antigens or cell-surface receptors | ERBB2, EGFR, ERBB4 | TUBB4A 1372/4885TUBB 1593/4885TUBA3C 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.